Literature DB >> 22101177

Massive obstetric haemorrhage with disseminated intravascular coagulopathy.

Lin Lin Su1, Yap Seng Chong.   

Abstract

Massive obstetric haemorrhage is a major contributor towards maternal morbidity and mortality. The main causes are abruptio placentae, placenta praevia and postpartum haemorrhage. Clinicians managing pregnant women should be equipped with the knowledge and skills for managing massive obstetric haemorrhage to institute timely and appropriate life-saving treatment. Prompt resuscitation and reversal of coagulopathy are critical while definitive measures are carried out to arrest the bleeding. Massive antepartum haemorrhage necessitates deliveries whereas interventions for postpartum haemorrhage range from medical to surgical measures. Algorithms such as haemostasis are useful aids to the systematic and stepwise management of postpartum haemorrhage. Surgical measures used to avoid peripartum haemorrhage include uterine compression sutures, uterine balloon tamponade, uterine artery, and internal iliac artery ligation. Tranexamic acid and recombinant factor VII are more recent medical interventions in massive postpartum haemorrhage. Education, regular drills and adherence to guidelines and protocols are important to reduce haemorrhage-related maternal deaths.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22101177     DOI: 10.1016/j.bpobgyn.2011.10.008

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  2 in total

1.  A Rare Case of A2+ve Blood Group in an Obstetric Emergency.

Authors:  Padmasri R; Urvashi Bhatara; Rupa S Iyengar
Journal:  J Clin Diagn Res       Date:  2014-02-03

2.  Maternal care quality in near miss and maternal mortality in an academic public tertiary hospital in Yogyakarta, Indonesia: a retrospective cohort study.

Authors:  Yuli Mawarti; Adi Utarini; Mohammad Hakimi
Journal:  BMC Pregnancy Childbirth       Date:  2017-05-22       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.